120 related articles for article (PubMed ID: 23600529)
1. Nitric oxide as a marker for evaluation of treatment effect of cyclosporine A in patients with bladder pain syndrome/interstitial cystitis type 3C.
Ehrén I; Hallén Grufman K; Vrba M; Sundelin R; Lafolie P
Scand J Urol; 2013 Dec; 47(6):503-8. PubMed ID: 23600529
[TBL] [Abstract][Full Text] [Related]
2. Bladder pain syndrome/interstitial cystitis ESSIC type 3C: high expression of inducible nitric oxide synthase in inflammatory cells.
Logadottir Y; Hallsberg L; Fall M; Peeker R; Delbro D
Scand J Urol; 2013 Feb; 47(1):52-6. PubMed ID: 22775390
[TBL] [Abstract][Full Text] [Related]
3. Inflammation characteristics in bladder pain syndrome ESSIC type 3C/classic interstitial cystitis.
Logadottir Y; Delbro D; Lindholm C; Fall M; Peeker R
Int J Urol; 2014 Apr; 21 Suppl 1():75-8. PubMed ID: 24807505
[TBL] [Abstract][Full Text] [Related]
4. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment.
Liu HT; Tyagi P; Chancellor MB; Kuo HC
BJU Int; 2009 Nov; 104(10):1476-81. PubMed ID: 19522864
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis/bladder pain syndrome.
Shie JH; Liu HT; Wang YS; Kuo HC
BJU Int; 2013 Apr; 111(4):638-46. PubMed ID: 22943596
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, Side Effects, and Monitoring of Oral Cyclosporine in Interstitial Cystitis-Bladder Pain Syndrome.
Crescenze IM; Tucky B; Li J; Moore C; Shoskes DA
Urology; 2017 Sep; 107():49-54. PubMed ID: 28528859
[TBL] [Abstract][Full Text] [Related]
7. Potassium sensitivity test (PST) as a measurement of treatment efficacy of painful bladder syndrome/interstitial cystitis: a prospective study with cyclosporine A and pentosan polysulfate sodium.
Sairanen J; Tammela TL; Leppilahti M; Onali M; Forsell T; Ruutu M
Neurourol Urodyn; 2007; 26(2):267-70. PubMed ID: 17078084
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide as an objective marker for evaluation of treatment response in patients with classic interstitial cystitis.
Hosseini A; Ehrén I; Wiklund NP
J Urol; 2004 Dec; 172(6 Pt 1):2261-5. PubMed ID: 15538244
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine A for refractory interstitial cystitis/bladder pain syndrome: experience of 3 tertiary centers.
Forrest JB; Payne CK; Erickson DR
J Urol; 2012 Oct; 188(4):1186-91. PubMed ID: 22901569
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine in severe interstitial cystitis.
Forsell T; Ruutu M; Isoniemi H; Ahonen J; Alfthan O
J Urol; 1996 May; 155(5):1591-3. PubMed ID: 8627830
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome.
Bosch PC
J Urol; 2014 Jan; 191(1):77-82. PubMed ID: 23792149
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological management of interstitial cystitis /bladder pain syndrome and the role cyclosporine and other immunomodulating drugs play.
Ogawa T; Ishizuka O; Ueda T; Tyagi P; Chancellor MB; Yoshimura N
Expert Rev Clin Pharmacol; 2018 May; 11(5):495-505. PubMed ID: 29575959
[TBL] [Abstract][Full Text] [Related]
13. Cytokine expression in patients with bladder pain syndrome/interstitial cystitis ESSIC type 3C.
Logadottir Y; Delbro D; Fall M; Gjertsson I; Jirholt P; Lindholm C; Peeker R
J Urol; 2014 Nov; 192(5):1564-8. PubMed ID: 24813342
[TBL] [Abstract][Full Text] [Related]
14. Effect of amitriptyline in treatment interstitial cystitis or bladder pain syndrome according to two criteria: does ESSIC criteria change the response rate?
Sun Y; Fang Z; Ding Q; Zheng J
Neurourol Urodyn; 2014 Mar; 33(3):341-4. PubMed ID: 23744795
[TBL] [Abstract][Full Text] [Related]
15. Effect of supplementation with hydrogen-rich water in patients with interstitial cystitis/painful bladder syndrome.
Matsumoto S; Ueda T; Kakizaki H
Urology; 2013 Feb; 81(2):226-30. PubMed ID: 23374763
[TBL] [Abstract][Full Text] [Related]
16. Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome.
Nickel JC; Hanno P; Kumar K; Thomas H
Urology; 2012 Jun; 79(6):1220-4. PubMed ID: 22516357
[TBL] [Abstract][Full Text] [Related]
17. Increased vascular endothelial growth factor expression in patients with bladder pain syndrome/interstitial cystitis: its association with pain severity and glomerulations.
Kiuchi H; Tsujimura A; Takao T; Yamamoto K; Nakayama J; Miyagawa Y; Nonomura N; Takeyama M; Okuyama A
BJU Int; 2009 Sep; 104(6):826-31; discussion 831. PubMed ID: 19298410
[TBL] [Abstract][Full Text] [Related]
18. Localization and expression of inducible nitric oxide synthase in biopsies from patients with interstitial cystitis.
Koskela LR; Thiel T; Ehrén I; De Verdier PJ; Wiklund NP
J Urol; 2008 Aug; 180(2):737-41. PubMed ID: 18554637
[TBL] [Abstract][Full Text] [Related]
19. Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome: a comparative randomized assessment of different regimens.
Lai MC; Kuo YC; Kuo HC
Int J Urol; 2013 Feb; 20(2):203-7. PubMed ID: 22925498
[TBL] [Abstract][Full Text] [Related]
20. Intravesical botulinum toxin a injections do not benefit patients with ulcer type interstitial cystitis.
Lee CL; Kuo HC
Pain Physician; 2013; 16(2):109-16. PubMed ID: 23511677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
